Nanexa AB (publ) (NANEXA.ST)
SEK 2.54
(-5.22%)
SEK 2.54
(-5.22%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 135.78 Million SEK | -85.3% |
| 2022 | 61.7 Million SEK | 54.62% |
| 2021 | 39.9 Million SEK | -5.18% |
| 2020 | 42.08 Million SEK | 96.58% |
| 2019 | 21.4 Million SEK | 41.05% |
| 2018 | 15.17 Million SEK | 37.04% |
| 2017 | 11.07 Million SEK | 32.91% |
| 2016 | 8.33 Million SEK | 33.88% |
| 2015 | 6.22 Million SEK | 836.31% |
| 2014 | 664.73 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 16.86 Million SEK | -3.11% |
| 2024 Q1 | 17.4 Million SEK | -73.61% |
| 2023 Q3 | 20.23 Million SEK | -25.46% |
| 2023 Q4 | 65.94 Million SEK | 225.96% |
| 2023 FY | 9.07 Million SEK | -85.3% |
| 2023 Q1 | 15.71 Million SEK | 787.41% |
| 2023 Q2 | 27.14 Million SEK | 72.7% |
| 2022 Q2 | 15.94 Million SEK | 27.84% |
| 2022 FY | 61.7 Million SEK | 54.62% |
| 2022 Q4 | 1.77 Million SEK | -91.55% |
| 2022 Q3 | 20.96 Million SEK | 31.52% |
| 2022 Q1 | 12.46 Million SEK | 265.34% |
| 2021 Q2 | 13.39 Million SEK | 15.51% |
| 2021 Q1 | 11.59 Million SEK | -12.48% |
| 2021 FY | 39.9 Million SEK | -5.18% |
| 2021 Q4 | 3.41 Million SEK | -70.35% |
| 2021 Q3 | 11.51 Million SEK | -14.04% |
| 2020 FY | 42.08 Million SEK | 96.58% |
| 2020 Q1 | 7.26 Million SEK | -6.95% |
| 2020 Q3 | 10.18 Million SEK | -10.62% |
| 2020 Q4 | 13.24 Million SEK | 30.08% |
| 2020 Q2 | 11.39 Million SEK | 56.79% |
| 2019 Q2 | 4.93 Million SEK | 18.07% |
| 2019 Q1 | 4.18 Million SEK | -24.1% |
| 2019 FY | 21.4 Million SEK | 41.05% |
| 2019 Q3 | 4.47 Million SEK | -9.37% |
| 2019 Q4 | 7.8 Million SEK | 74.46% |
| 2018 Q3 | 2.99 Million SEK | -11.73% |
| 2018 Q1 | 3.27 Million SEK | 2.99% |
| 2018 Q2 | 3.39 Million SEK | 3.48% |
| 2018 Q4 | 5.51 Million SEK | 84.01% |
| 2018 FY | 15.17 Million SEK | 37.04% |
| 2017 Q2 | 2.89 Million SEK | 15.16% |
| 2017 FY | 11.07 Million SEK | 32.91% |
| 2017 Q4 | 3.18 Million SEK | 28.27% |
| 2017 Q3 | 2.48 Million SEK | -14.27% |
| 2017 Q1 | 2.51 Million SEK | -4.11% |
| 2016 Q1 | 1.91 Million SEK | -16.04% |
| 2016 Q2 | 1.95 Million SEK | 2.04% |
| 2016 FY | 8.33 Million SEK | 33.88% |
| 2016 Q4 | 2.62 Million SEK | 42.17% |
| 2016 Q3 | 1.84 Million SEK | -5.63% |
| 2015 Q3 | 1.43 Million SEK | -24.26% |
| 2015 Q1 | 550 Thousand SEK | 81.36% |
| 2015 Q2 | 1.89 Million SEK | 244.0% |
| 2015 Q4 | 2.28 Million SEK | 59.17% |
| 2015 FY | 6.22 Million SEK | 836.31% |
| 2014 Q3 | 383 Thousand SEK | 391.03% |
| 2014 FY | 664.73 Thousand SEK | 0.0% |
| 2014 Q2 | 78 Thousand SEK | 0.0% |
| 2014 Q4 | 303.26 Thousand SEK | -20.82% |
| 2014 Q1 | 78 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AcuCort AB | 13.24 Million SEK | -924.847% |
| AlzeCure Pharma AB (publ) | 38.26 Million SEK | -254.874% |
| BioGaia AB (publ) | 507.08 Million SEK | 73.223% |
| Enzymatica AB (publ) | 79.92 Million SEK | -69.887% |
| Enorama Pharma AB (publ) | 38.22 Million SEK | -255.208% |
| Gabather AB (publ) | 9.47 Million SEK | -1333.207% |
| Klaria Pharma Holding AB (publ.) | 14.88 Million SEK | -812.268% |
| Moberg Pharma AB (publ) | 27.46 Million SEK | -394.418% |
| Newbury Pharmaceuticals AB (publ) | 30.11 Million SEK | -350.938% |
| ODI Pharma AB | -5.00 SEK | 2715640100.0% |
| Orexo AB (publ) | 659.4 Million SEK | 79.408% |
| Probi AB (publ) | 208.93 Million SEK | 35.012% |
| Swedencare AB (publ) | 1.12 Billion SEK | 87.96% |
| Swedish Orphan Biovitrum AB (publ) | 9.39 Billion SEK | 98.555% |
| Toleranzia AB | 6.97 Million SEK | -1847.533% |
| Vivesto AB | 355.71 Million SEK | 61.829% |